Regulated expression and intracellular localization of cystatin F in human U937 cells.
Cystatin F is a cysteine peptidase inhibitor recently discovered in haematopoietic cells by cDNA cloning. To further investigate the expression, distribution and properties of the native human inhibitor the promyeloid cell line U937 has been studied. The cells expressed relatively large quantities of cystatin F, which was found both secreted and intracellularly. The intracellular levels were unusually high for a secreted cystatin ( approximately 25% of the cystatin F in 2- or 4-day culture medium). By contrast, U937 cells contained only 3-4% of the related inhibitor, cystatin C. Cystatin F purified from lysates of U937 cells showed three major forms carrying two, one or no carbohydrate chains. Immunocytochemistry demonstrated a marked cytoplasmic cystatin F staining in a granular pattern. Double staining with a marker for endoplasmic reticulum revealed no colocalization for cystatin F. Analysis of the promoter region of the cystatin F gene (CST7) showed that it, like that of the cystatin C gene (CST3), is devoid of typical TATA- and CAAT-box elements. In contrast to the cystatin C promoter, it does not contain multiple Sp1 binding sites, but has a unique site for C/EBPalpha, possibly explaining the restricted expression of the cystatin F gene. Cells stimulated with all-trans retinoic acid to differentiate them towards a granulocytic pathway, showed a strong ( approximately 18-fold) down-regulation of intracellular cystatin F and almost abolished secreted levels of the inhibitor. Stimulation with tetradecanoyl phorbol acetate, causing monocytic differentiation, also resulted in down-regulation (two fold to threefold) of cystatin F expression, whereas the cystatin C expression was essentially unaltered in both experiments. The results suggest that cystatin F as an intracellular cysteine peptidase inhibitor with readily regulated expression, may be a candidate to control the cysteine peptidase activity known to be essential for antigen presentation in different blood cell lineages.
Nathanson
Carl-Michael
CM
Department of Clinical Chemistry, Institute of Laboratory Medicine, and Department of Ophtalmology, University of Lund, University Hospital, Lund, Sweden.
Wassélius
Johan
J
Wallin
Hanna
H
Abrahamson
Magnus
M
D001665:Binding Sites; D014408:Biomarkers, Tumor; D015152:Blotting, Northern; D015153:Blotting, Western; D055316:Cystatin C; D015891:Cystatins / Q000096:biosynthesis* / Q000737:chemistry* / Q000235:genetics; D018076:DNA, Complementary / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D007150:Immunohistochemistry; D007700:Kinetics; D008856:Microscopy, Fluorescence; D011401:Promoter Regions, Genetic; D012313:RNA / Q000378:metabolism; D013347:Subcellular Fractions; D013997:Time Factors; D020298:U937 Cells
D014408:Biomarkers, Tumor; C525030:CST3 protein, human; C116891:CST7 protein, human; D055316:Cystatin C; D015891:Cystatins; D018076:DNA, Complementary; D012313:RNA